Clinical Trial Update: Impact of SGLT2 Inhibitors in Heart Transplant Recipients [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the impact of SGLT2 inhibitors in heart transplant recipients, investigating effects on heart failure, cardiac allograft vasculopathy, a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Allograft Vasculopathy
• Heart Failure
• Heart Transplant Rejection

Drugs mentioned

• FARXIGA (dapagliflozin)
• INVOKANA (CANAGLIFLOZIN)
• Jardiance (empagliflozin)
• STEGLATRO (ertugliflozin)

Snippet

Sponsor: Universidade Federal do Ceara | Conditions: Transplant; Failure, Heart, Cardiac Allograft Vasculopathy | Phase 2 | Status: ENROLLING_BY_INVITATION